Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Arunava Chakravartty et al.|New England Journal of Medicine|2019Cited by 1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Seock‐Ah Im et al.|The Lancet Oncology|2018Cited by 1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Do‐Youn Oh et al.|The Lancet Oncology|2023Cited by 614
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, Dana E. Rathkopf et al.|Journal of Clinical Oncology|2023Cited by 317
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216